定制化光屈光性角膜切削术联合交联对比单纯交联治疗进展性圆锥角膜的疗效:系统综述与Meta分析
该系统综述与Meta分析纳入8项非随机研究共731只眼(706例患者),比较定制化光屈光性角膜切削术联合角膜交联(CXL+cPRK)与单纯CXL治疗进展性圆锥角膜的疗效。结果显示CXL+cPRK在未矫正远视力(UDVA)、矫正远视力(CDVA)、屈光柱镜、彗差、总高阶像差、平均角膜曲率(KM)及中央角膜厚度(CCT)方面优于单纯CXL,内皮细胞计数及进展率两组无显著差异。
要点
- CXL+cPRK较单纯CXL显著改善术后UDVA(SMD=-0.39,95%CI -0.69至-0.08,P=.01)和CDVA(SMD=-0.57,95%CI -0.96至-0.18,P=.004)。
- CXL+cPRK还降低屈光柱镜、彗差、总高阶像差、彗差样像差、平均角膜曲率和中央角膜厚度,两组内皮细胞计数无显著差异。
- 两组术后扩张进展率相当;所有纳入研究至少一个ROBINS-I领域为高偏倚风险,尤其与混杂相关。
核心结论
- 在进展性圆锥角膜的管理中,定制化PRK联合CXL较单纯CXL提供更优的术后视力(UDVA、CDVA)和视觉质量,同时维持相同的角膜稳定性。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、PubMed、Cochrane Library和EMBASE至2024年9月,遵循PRISMA指南,计划纳入随机对照试验及比较性非随机前瞻性或回顾性研究,但仅检索到非随机研究。
- 纳入8项非随机研究,共731只眼(706例患者),比较CXL+cPRK与单纯CXL,最短随访6个月,使用ROBINS-I工具评估偏倚风险,采用标准化均数差(SMD)及95%置信区间(CI)进行Meta分析,必要时使用随机效应模型,采用留一法进行敏感性分析。
- 研究注册于PROSPERO数据库(CRD42024594757)。
主要发现
- 与单纯CXL相比,CXL+cPRK显著改善术后UDVA(SMD=-0.39,95%CI -0.69至-0.08,P=.01)和CDVA(SMD=-0.57,95%CI -0.96至-0.18,P=.004),并降低屈光柱镜误差。
- CXL+cPRK还降低彗差、总高阶像差、彗差样像差、平均角膜曲率(KM)和中央角膜厚度(CCT)。
- 两组内皮细胞计数(ECC)无显著差异,术后扩张进展率两组相当。
- 所有纳入研究至少一个ROBINS-I领域为高偏倚风险,尤其与混杂相关;异质性主要归因于手术技术、患者选择标准和研究设计的差异。
关键数值与推荐
- 主要结局为未矫正远视力(UDVA)和矫正远视力(CDVA),次要结局包括屈光、角膜结构和高阶像差(HOA)。
- CXL+cPRK组UDVA的SMD=-0.39(95%CI -0.69至-0.08,P=.01),CDVA的SMD=-0.57(95%CI -0.96至-0.18,P=.004),均优于单纯CXL组。
- 两组内皮细胞计数无显著差异,术后扩张进展率相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仅检索到非随机研究,所有纳入研究至少一个ROBINS-I领域为高偏倚风险,尤其与混杂相关。
- 异质性主要归因于手术技术、患者选择标准和研究设计的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: This review evaluates the effectiveness and safety of combining cPRK with CXL versus CXL alone in improving visual outcomes for patients with progressive keratoconus. DESIGN: Systematic review and meta-analysis. CLINICAL RELEVANCE: Keratoconus leads to vision loss and affects quality of life. While CXL is the current standard for halting progression, it does not correct the visual impairment. This review explores whether adding cPRK to CXL offers better visual outcomes while maintaining the same safety, potentially refining treatment approaches. METHODS: A systematic search of MEDLINE, PubMed, Cochrane Library and EMBASE was conducted through September 2024, following PRISMA guidelines. The initial study design aimed to include randomized controlled trials (RCTs) as well as comparative nonrandomized prospective or retrospective studies evaluating CXL+cPRK versus CXL alone, with a minimum follow-up of six months. However, only nonrandomized studies were retrieved. As a result, all included studies were assessed for the risk of bias using the ROBINS-I tool. The primary outcomes were uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA). Secondary outcomes included refraction, corneal structure, and higher-order aberrations (HOA). Meta-analysis was performed using standardized mean differences (SMD) with 95% confidence intervals (CI), and heterogeneity was assessed using a random-effects model where necessary. Sensitivity analysis was conducted using a leave-one-out approach to assess the robustness of the results. This study is registered in the PROSPERO database (CRD42024594757). RESULTS: Eight nonrandomized studies involving 731 eyes from 706 patients were analyzed. Compared to CXL alone, the combination of CXL+cPRK significantly improved postoperative UDVA (SMD = -0.39, 95% CI: -0.69 to -0.08, P = .01) and CDVA (SMD = -0.57, 95% CI: -0.96 to -0.18, P = .004), while also reducing refractive cylinder error. Additionally, CXL+cPRK led to reductions in coma, total HOA, coma-like aberrations, mean keratometry (KM), and central corneal thickness (CCT). No significant differences were observed between the groups in endothelial cell count (ECC). The rate of postoperative ectasia progression was comparable between both groups. All included studies exhibited at least one ROBINS-I domain at high risk of bias, particularly related to confounding. The heterogeneity observed in this analysis was primarily attributed to differences in surgical techniques, patient selection criteria, and study designs across the included studies. CONCLUSIONS: Customized PRK combined with CXL provides superior postoperative visual acuity (UDVA, CDVA) and visual quality compared to CXL alone while maintaining the same corneal stability in the management of progressive keratoconus. Only nonrandomized studies could be retrieved for the purpose of the study.
引用
- Zhang H, Cantó-Cerdán M, Félix-Espinar B, et al. Efficacy of Customized Photorefractive Keratectomy With Cross-Linking Versus Cross-Linking Alone in Progressive Keratoconus: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025. PMID: 40023354. doi:10.1016/j.ajo.2025.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。